Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 120 peer-reviewed journal articles Updated
Oncology

Your First Steps with ALCL: Understanding the Diagnosis

At a Glance

Anaplastic Large Cell Lymphoma (ALCL) is a rare but highly treatable non-Hodgkin T-cell lymphoma characterized by the CD30 protein marker. Modern targeted therapies, like brentuximab vedotin, and excellent outcomes for ALK-positive and BIA-ALCL subtypes offer a very optimistic outlook.

Receiving a diagnosis of Anaplastic Large Cell Lymphoma (ALCL) can feel like the world has suddenly shifted [1]. It is a rare and serious diagnosis, but it is also a disease that modern medicine has become exceptionally good at treating [2][3]. This page is designed to help you catch your breath, understand the basic terms, and see the clear path forward that your medical team is already building.

What is ALCL?

ALCL is a type of non-Hodgkin lymphoma, a cancer that begins in the white blood cells of the immune system [4]. Specifically, it is a T-cell lymphoma, meaning it affects the T-cells that normally help your body fight off infections [5].

To confirm this diagnosis, doctors look for a specific protein on the surface of the cancer cells called CD30 [6][7]. Think of CD30 as a “marker” or a “flag.” Because ALCL cells almost always fly this flag, doctors can use specialized treatments that act like heat-seeking missiles to find and destroy only the cells carrying that marker [8][3].

How Rare Is It?

ALCL is considered a rare disease. In children, it makes up about 10% to 15% of all childhood lymphomas [9]. In adults, it is even less common, representing a small fraction of all diagnosed lymphomas [6]. Because it is rare, it is essential to work with a medical team that specializes in lymphoma [10].

Three Stabilizing Facts

While the initial news is overwhelming, three major advancements have fundamentally changed the outlook for patients with ALCL.

1. ALK-Positive ALCL is Highly Treatable

Most systemic cases of ALCL (meaning those found in the lymph nodes or organs) are divided into two groups based on a protein called Anaplastic Lymphoma Kinase (ALK) [6][5].

  • ALK-positive (ALK+): This version is more common in children and young adults [11]. It typically responds very well to standard chemotherapy and has an excellent long-term cure rate [12][13].
  • ALK-negative (ALK-): While historically considered more challenging, new targeted therapies have significantly improved the outlook for these patients [3].

2. Targeted Therapy Has Changed the Game

For decades, the “standard” treatment was a combination of chemotherapies known as CHOP. However, a landmark clinical trial called ECHELON-2 changed everything [8][14]. It proved that adding a targeted drug called brentuximab vedotin (BV) to chemotherapy was much more effective than chemotherapy alone [3][2]. BV works by latching onto that CD30 “flag” mentioned earlier and delivering medicine directly into the cancer cell [8]. This approach is now the preferred standard of care for many patients [7][15].

3. BIA-ALCL Has an Excellent Prognosis

A specific, very rare version called Breast Implant-Associated ALCL (BIA-ALCL) can occur in people with textured breast implants [10][16]. While frightening, BIA-ALCL is usually caught early because it often presents as swelling around the implant [17][18]. For the vast majority of patients, complete surgical removal of the implant and the surrounding scar tissue (the capsule) is the only treatment needed to achieve a full recovery [5][19][20].

Moving Forward

You are likely in the middle of “staging,” which involves scans and tests to see where the lymphoma is located [21]. This process is vital for choosing the right treatment plan. While the next few weeks will be busy, remember that ALCL is a disease that doctors now have powerful, targeted tools to fight [2][22].

Navigating Your Guide

To help you understand your diagnosis and treatment, we have created the following resources:

01

Symptoms & Diagnosis: Getting the Right Answer

Learn about Anaplastic Large Cell Lymphoma (ALCL) symptoms and the diagnostic process. Understand B-symptoms, CD30 testing, and why excisional biopsies matter.

02

Understanding the 4 Subtypes: Location and Behavior

Learn about the four main subtypes of Anaplastic Large Cell Lymphoma (ALCL), including ALK-positive, ALK-negative, BIA-ALCL, and primary cutaneous ALCL.

03

Pathology & Genetics: Decoding Your Report

Learn how to read your Anaplastic Large Cell Lymphoma (ALCL) pathology report. Understand CD30, ALK status, hallmark cells, and genetic markers like DUSP22.

04

Treatment Strategies for Adults: Standard of Care

Learn about the standard of care for adult Anaplastic Large Cell Lymphoma (ALCL). Understand treatments like BV-CHP, BIA-ALCL surgery, and ALK inhibitors.

05

Pediatric ALCL: A Guide for Parents

Learn about pediatric Anaplastic Large Cell Lymphoma (ALCL) treatments. Understand standard chemotherapy protocols, MDD testing, and targeted therapies.

06

Survivorship & Monitoring: Life After Treatment

Learn what to expect during ALCL survivorship. Understand your follow-up schedule, how to monitor for relapse, and manage late side effects like neuropathy.

Common questions in this guide

What is Anaplastic Large Cell Lymphoma (ALCL)?
ALCL is a rare type of non-Hodgkin lymphoma that begins in the T-cells of your immune system. These cancer cells typically carry a specific protein marker called CD30 on their surface, which doctors use to confirm the diagnosis and target treatments.
Is ALK-positive ALCL curable?
Yes, ALK-positive ALCL typically responds very well to standard treatments. It is highly treatable and has an excellent long-term cure rate, particularly for children and young adults.
How has ALCL treatment improved recently?
Treatment has significantly improved with the addition of targeted therapies like brentuximab vedotin. This drug acts like a heat-seeking missile to find and destroy cancer cells carrying the CD30 marker, which has proven much more effective than traditional chemotherapy alone.
What is the treatment for breast implant-associated ALCL (BIA-ALCL)?
BIA-ALCL is a very rare form that occurs around textured breast implants. For the vast majority of patients, complete surgical removal of the implant and the surrounding scar tissue is the only treatment needed to achieve a full recovery.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my (or my child's) ALK status, and how does that influence our specific treatment plan?
  2. 2.Given the ECHELON-2 trial results, will brentuximab vedotin be part of the first-line treatment?
  3. 3.Is our care team following the latest NCCN or Children's Oncology Group (COG) guidelines for ALCL?
  4. 4.For ALK-negative cases, has molecular testing for DUSP22 or TP63 rearrangements been performed to better understand the prognosis?
  5. 5.If this is BIA-ALCL, was the surgical resection 'en bloc' (complete), and do we need any further treatment?
  6. 6.Are there fertility preservation options we should consider before starting chemotherapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    A challenging case of ALK-negative anaplastic large cell lymphoma in a 12-year-old boy: A rare case report from Syria.

    Abdul Rahman SA, Loutfi K, Turk T, et al.

    Annals of medicine and surgery (2012) 2022; (79()):104085 doi:10.1016/j.amsu.2022.104085.

    PMID: 35860076
  2. 2

    Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.

    Nizamuddin I, Galvez C, Pro B

    Seminars in hematology 2021; (58(2)):85-94 doi:10.1053/j.seminhematol.2021.02.006.

    PMID: 33906726
  3. 3

    Frontline Management of Nodal Peripheral T-Cell Lymphomas.

    Ngu HS, Savage KJ

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2023; (43()):e390334 doi:10.1200/EDBK_390334.

    PMID: 37262395
  4. 4

    Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma.

    Blombery P, Thompson ER, Jones K, et al.

    Haematologica 2016; (101(9)):e387-90 doi:10.3324/haematol.2016.146118.

    PMID: 27198716
  5. 5

    Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

    Turner SD, Inghirami G, Miranda RN, Kadin ME

    The American journal of pathology 2020; (190(1)):2-10 doi:10.1016/j.ajpath.2019.09.005.

    PMID: 31610171
  6. 6

    ALK-negative anaplastic large-cell lymphoma.

    Gaulard P, de Leval L

    Blood 2016; (127(2)):175-7 doi:10.1182/blood-2015-11-676916.

    PMID: 26769771
  7. 7

    Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.

    Martinez-Calle N, Kirkwood AA, Lamb M, et al.

    Advances in therapy 2021; (38(7)):3789-3802 doi:10.1007/s12325-021-01764-0.

    PMID: 34037958
  8. 8

    Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy.

    Moskowitz AJ

    Hematology. American Society of Hematology. Education Program 2018; (2018(1)):207-212 doi:10.1182/asheducation-2018.1.207.

    PMID: 30504312
  9. 9

    ALK-positive anaplastic large cell lymphoma presenting as an endobronchial polyp in a pediatric patient.

    Venkatappa HA, Nargund A, Okaly GVP, et al.

    International cancer conference journal 2025; (14(4)):513-517 doi:10.1007/s13691-025-00805-7.

    PMID: 41395554
  10. 10

    Breast Implant-Associated Anaplastic Large Cell Lymphoma: Two Distinct Clinical Presentations.

    Miranda P, Moita F, Vargas Moniz J, Rodrigues Dos Santos C

    Acta medica portuguesa 2022; (35(11)):835-839 doi:10.20344/amp.16578.

    PMID: 35584637
  11. 11

    Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma.

    Khanlari M, Li S, Miranda RN, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022; (35(3)):412-418 doi:10.1038/s41379-021-00944-1.

    PMID: 34628481
  12. 12

    Anaplastic lymphoma kinase-negative primary systemic anaplastic large cell lymphoma mimicking a ruptured epidermal cyst of the scalp: a case report and literature review.

    Ahn IY, Bae TH, Kang SH, et al.

    Archives of craniofacial surgery 2024; (25(6)):298-302 doi:10.7181/acfs.2024.00262.

    PMID: 39551572
  13. 13

    Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review.

    Noguchi K, Ikawa Y

    Cancers 2023; (15(24)) doi:10.3390/cancers15245733.

    PMID: 38136278
  14. 14

    BV and beyond: how to incorporate novel agents into PTCL management.

    Nizamuddin IA, Mehta-Shah N

    Hematology. American Society of Hematology. Education Program 2024; (2024(1)):54-61 doi:10.1182/hematology.2024000530.

    PMID: 39644004
  15. 15

    Recent advances and future perspectives in frontline treatment of peripheral T-cell lymphoma.

    Shirouchi Y, Yamauchi N, Maruyama D

    Japanese journal of clinical oncology 2026; (56(1)):24-32 doi:10.1093/jjco/hyaf158.

    PMID: 41066685
  16. 16

    Commentary on: Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

    Prince HM, Johnstone R

    Aesthetic surgery journal 2016; (36(7)):782-3 doi:10.1093/asj/sjw065.

    PMID: 27095311
  17. 17

    Use of flow cytometry and cytology to differentiate breast implant-associated anaplastic large cell lymphoma from reactive seromas in Brazilian patients.

    De Azambuja AP, Gevert F, Oliveira RM, et al.

    Cytometry. Part B, Clinical cytometry 2022; (102(4)):312-316 doi:10.1002/cyto.b.22040.

    PMID: 34791787
  18. 18

    Breast Implant-Associated Anaplastic Large Cell Lymphoma: Where Hematology and Plastic Surgery Meet.

    Joks MM, Czernikiewicz K, Mazurkiewicz Ł, et al.

    Clinical lymphoma, myeloma & leukemia 2024; (24(9)):e293-e300 doi:10.1016/j.clml.2024.05.008.

    PMID: 38839449
  19. 19

    Coming of Age: Breast Implant-Associated Anaplastic Large Cell Lymphoma After 18 Years of Investigation.

    Clemens MW, Miranda RN

    Clinics in plastic surgery 2015; (42(4)):605-13.

    PMID: 26408447
  20. 20

    Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management.

    St Cyr TL, Pockaj BA, Northfelt DW, et al.

    Plastic surgery (Oakville, Ont.) 2020; (28(2)):117-126 doi:10.1177/2292550320925906.

    PMID: 32596187
  21. 21

    Beyond surgery: the proper role and delivery of radiation therapy in the local-regional management of BIA-ALCL.

    Gunther JR, Iyer SP, Hunt KK, et al.

    Case reports in plastic surgery & hand surgery 2024; (11(1)):2389172 doi:10.1080/23320885.2024.2389172.

    PMID: 39119029
  22. 22

    Role of ALK Inhibitors in Anaplastic Large Cell Lymphoma-Experience from an Indian Center.

    Indhuja MV, Kesana S, Mehra N, et al.

    South Asian journal of cancer 2024; (13(2)):121-125 doi:10.1055/s-0042-1758353.

    PMID: 38919655

This guide is for informational purposes only and does not replace professional medical advice. Always discuss your ALCL diagnosis, ALK status, and specific treatment plan with your oncologist.

Get notified when new evidence is published on Anaplastic large cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.